Trials
1 active
6 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Parkinson's Disease (PD)
- Main trialPhase 2
- “The primary objectives of this study are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with Parkinson's Disease (PD).”In the company’s words, NCT06773962 on ClinicalTrials.gov
- Other names
- oloctinebart
Other drugs for Parkinson's Disease (PD)
- PembrolizumabMerck & Co. · Phase 3
- Sacituzumab govitecanGilead (Kite) · Phase 3
- Intismeran autogeneMerck & Co. · Moderna · Phase 3
- LenvatinibEisai · Merck & Co. · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
- BHV-8000Biohaven · Phase 2/3
Coming up1
- 28 NovPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 28 Nov 2026 | A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | |
| Phase 2Terminated | 17 Nov 2023 | A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease | |
| Phase 2Withdrawn | 18 Dec 2023 | A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke | |
| Phase 1/2Completed | 13 Oct 2022 | Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease | |
| Phase 1Withdrawn | 1 Sep 2021 | Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19 | |
| Phase 1Completed | 3 May 2022 | Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026